M&A / Deals UCB cuts $1.15bn deal to buy epilepsy biotech Neurona PharmaphorumUCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy. M&A / DealsNeuroscienceRead full story Post navigation Previous: Magazine: Digital twins become the new battleground for CDMOsNext: UCB to purchase Neurona and NRTX-1001 for $1.15bn Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026